Log In
Print this Print this

Biosimilar bevacizumab (BEVZ92)

  Manage Alerts
Collapse Summary General Information
Company Chemo Group
DescriptionBiosimilar of bevacizumab, a humanized mAb against VEGF
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of ActionVascular endothelial growth factor (VEGF) inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationColorectal cancer
Indication DetailsTreat metastatic colorectal cancer (mCRC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today